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carriage rate of TNF2 when compared with patients withoutImpact of interleukin-1 receptor antagonist and tumor necrosis
gross hematuria (allele frequency, 15.4 vs. 4.6%, P 5 0.0552;factor-a gene polymorphism on IgA nephropathy.
carriage rate, 30.8% vs. 8.2%, P 5 0.0272). Renal survival analy-Background. It is evident that cytokines play an important
sis revealed that the TNF2 carrier had a renal survival compara-role in the pathogenesis as well as disease progression in IgA
ble with TNF2 (2) patients. However, the carriage of thenephropathy (IgAN). The level of cytokine production is influ-
enced by different genotypes that reflect gene polymorphism IL1RN*2 allele was associated with a significantly poorer long-
of the pertinent cytokine. Interleukin-1 receptor antagonist term outcome with a median survival time of 72 months, as
(IL-1ra) and tumor necrosis factor-a (TNF-a) gene polymor- compared with those without IL1RN*2 (134 months, P , 0.01).
phism have been found to affect disease susceptibility and Conclusion. IL-1ra and TNF-a gene polymorphism may af-
activity in several inflammatory diseases. However, the impact fect disease susceptibility as well as disease activity and long-
of these polymorphisms in IgAN patients has not previously term outcome in human IgAN. Treatment with an IL-1ra or
been thoroughly studied. IL-1 blocking agent may be relevant in those carrying the
Methods. We investigated 111 cases of biopsy-proven IgAN IL1RN*2 allele.
and 100 healthy, normal controls for their IL-1ra and TNF-a
gene polymorphism. IL-1ra gene polymorphism was character-
ized as a variable number of tandem repeats of a 86 bp sequence
IgA nephropathy (IgAN) is the most common primarywithin intron 2. Five alleles were identified and were designated
as IL1RN*1, IL1RN*2, IL1RN*3, IL1RN*4, and IL1RN*5, glomerulonephritis in many countries, including Taiwan.
corresponding to 4, 2, 5, 3, 6 repeats, respectively. A polymor- The pathogenetic mechanism is still speculative and con-
phism in the promoter region of the TNF-a gene was also troversial [1]. Nevertheless, a great body of evidencestudied. This polymorphism involved a guanidine to adenosine
suggests that cytokines play an important role in thetransition at position 2308 and was designated as TNF1 (2308G)
pathogenesis and disease progression of IgAN [2–6]. In-and TNF2 (2308A).
Results. There were 54 male and 57 female patients with a terleukin-1 (IL-1) has been found to be expressed in the
mean age of 30.3 6 12.5 years and a disease duration of 66.8 6 glomeruli of IgAN patients [4, 6], and this may be a
47.2 months. The mean duration of the follow-up period was
marker of glomerular mesangial cell activation [5] in47.3 6 32.6 months. In the patient group, the allele frequencies
response to a nephritogenic immune complex. It hadof IL1RN*1, IL1RN*2, IL1RN*3, IL1RN*4, and IL1RN*5
were 89.6%, 9.9%, 0%, 0.5%, and 0%, respectively, whereas been shown that IL-1 is involved in mesangial cell prolif-
the corresponding carriage rates were 100%, 19.8%, 0%, 0.9%, eration [2] and extracellular matrix production [7]. IL-1
and 0%, respectively. An excessive carriage of IL2RN*2 was receptor antagonist (IL-1ra), a glycoprotein generated byfound in the patients when compared with normal controls
monocytes/macrophages and polymorphonuclear cells,(allele frequency, 9.9 vs. 2.5%, P , 0.0001). The allele frequen-
can inhibit IL-1 activity by competing for receptor bind-cies of TNF1 and TNF2 were 94.1 and 5.9%, respectively, and
the carriage rates were 99.1 and 10.8%, respectively, in the ing [8, 9]. IL-1ra has been shown to suppress experimen-
patients, which was not significantly different from those of tal glomerulonephritis [10, 11] and IgAN [12]. The IL-
normal controls. When the patients were stratified into mild
1ra gene has been found to have a variable numberand severe groups according to their initial presentation, none
of tandem repeat polymorphism in intron 2 [13]. Theof the studied alleles correlated with the severity. However,
patients with gross hematuria were associated with a higher presence of the two-repeat allele (IL1RN*2) in individu-
als has been shown to be associated with several inflam-
matory diseases, such as psoriasis [14], alopecia areataKey words: cytokine gene polymorphism, progressive renal disease,
glomerulonephritis, inflammation. [15], ulcerative colitis [16], systemic lupus erythemato-
sus [17], Graves’ disease [18], as well as diabetic compli-Received for publication January 14, 1999
cation [19]. Recently, an excessive carriage of IL1RN*2and in revised form October 11, 1999
Accepted for publication March 10, 2000 was found in IgAN patients with gross hematuria and
Henoch-Scho¨nlein purpura [20], suggesting a genetic linkÓ 2000 by the International Society of Nephrology
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between these two diseases. The impact of carriage of
IL1RN*2 on the long-term outcome in IgAN, however,
has yet to be addressed.
Tumor necrosis factor-a (TNF-a) is also a proinflam-
matory cytokine that has been involved in the pathogene-
sis of glomerulonephritis, including IgAN [4, 6, 21]. A
gene polymorphism at position 2308 in the promoter
region involving a transition of guanidine to adenosine
has been characterized [22]. The 2308A polymorphism
(TNF2) is associated with an increased of TNF-a tran-
scription [23], which may predispose humans to the oc-
currence of inflammatory diseases. Carriage of TNF2 has
been shown to be associated with several inflammatory
diseases, including alopecia areata [24], rheumatoid ar- Fig. 1. Electrophoresis of the polymerase chain reaction (PCR) prod-
uct of the interleukin-1 receptor antagonist (IL-1ra) gene. Lanes 1, 2,thritis [25], and systemic lupus erythematosus [26]. The
3, and 5 are four-repeat (410 bp) homozygotes. Lane 4 is a heterozygoteeffect of TNF2 on the disease activity in IgAN has not
of four repeats and three repeats (325 bp). Lane 6 is a heterozygote of
been studied before. The aim of the present study was four repeats and two repeats (240 bp). M 5 DNA marker ladder.
to define the impact of IL-1ra and TNF-a gene polymor-
phism on disease activity as well as on the long-term
outcome of IgAN.
the apparent onset of disease, such as gross hematuria
or abnormal urinalysis, and the end of the follow-up
METHODS period. The duration of follow-up was defined as the
Patients duration between kidney biopsy and the end of the fol-
Patients with biopsy-proven IgAN were retrospec- low-up period. Because a few cases were presented as
tively studied for their IL-1ra and TNF-a gene polymor- end-stage renal failure without a clear-cut history, the
phism. To enroll only those with a longer term of follow- previously mentioned duration was given as 0.
up, patients undergoing biopsy after 1995 were excluded.
Polymerase chain reactionUp to 1994, there were 215 cases of biopsy-proven IgAN,
of which only 111 cases had a clear-cut history and ade- Genomic DNA was extracted from peripheral blood
quate follow-up data to be analyzed and formed the basis mononuclear cells using DNAzol reagent (GIBCO BRL,
of this study. Patients were either referred from local Grand Island, NY, USA). IL-1ra genotyping was based
clinics or were seen in our hospital from the very begin- on the method by Tarlow et al [13] and TNF-a genotyp-
ning. It is our policy that all of the patients with unex- ing according to Wilson et al [22]. Briefly, the polymerase
plained hematuria and/or proteinuria were advised to chain reaction (PCR) consisted of a denaturing at 948C
have a kidney biopsy. Informed consent was routinely for two minutes, then 30 cycles at 948C for 30 seconds,
obtained for every patient undergoing kidney biopsy. 608C for 30 seconds, and 728C for 45 seconds, and a final
According to the initial clinical presentation, patients extension at 728C for five minutes. The following primers
were stratified into two subgroups: mild, meaning a se-
were used: IL-1ra, 59-CTCAGCAACACTCCTAT-39 and
rum creatinine level of less than 1.3 mg/dL, a daily urine
59-CCTGGTCTGCAGGTAA-39; TNF-a, 59-AGGCAAprotein loss of less than 1.5 g, and normal blood pressure,
TAGGTTTTGAGGGCCAT-39 and 59-TCCTCCCTGCand severe, meaning the presence of a serum creatinine
TCCGATTCCG-39. The PCR products for IL-1ra werelevel .1.3 mg/dL, a daily urine protein loss .1.5 g, or
analyzed by electrophoresis on 2% agarose gels and werehypertension. To evaluate the impact of gene polymor-
stained with ethidium bromide for visualization underphism on disease progression, patients were subdivided
ultraviolet light. The polymorphism was based on theinto progressor and nonprogressor groups according to
number of repeats of an 86 bp sequence [13] and weretheir renal function profile at the last follow-up examina-
designated as IL1RN*1 (four repeats, 410 bp), IL1RN*2tion. Progressor meant patients with any of the following
(two repeats, 240 bp), IL1RN*3 (five repeats, 500 bp),pictures during follow-up: a steady increase of serum
IL1RN*4 (three repeats, 325 bp), and IL1RN*5 (six re-creatinine level, a 50% or more increase of daily urine
peats, 595 bp) (Fig. 1). PCR products for TNF-a wereprotein loss as compared with the baseline value, or the
digested overnight with NcoI (NEB) at 378C and wereappearance of hypertension in a previously normoten-
analyzed on 4% NuSieve 3:1 agarose gels (FMC Biopro-sive patient. Nonprogressor meant patients who had a
ducts, Rockland, ME, USA). The polymorphism wasstable renal disease or those who were in remission.
Disease duration was defined as the duration between designated as TNF1 (2308G), which gave two fragments
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Age years (range) 30.3612.5 (10–69)
Disease duration months (range) 66.8647.2 (0–288)
Follow-up duration months (range) 47.3632.6 (0–132)
Table 2. Allele frequency and carriage rate
Allele frequency % Carriage rate %
Control IgAN Control IgAN
IL1RN*1 96.5 89.6 99.0 100
IL1RN*2 2.5 9.9a 4.0 19.8a
IL1RN*3 0 0 0 0
IL1RN*4 1.0 0.5 2.0 0.9
IL1RN*5 0 0 0 0
TNF1 88.0 94.1 98.0 99.1
TNF2 12.0 5.9 21.0 10.8
aP , 0.0001Fig. 2. Electrophoresis of the PCR product of the tumor necrosis fac-
tor-a (TNF-a) gene. Lanes 1 and 5 are homozygotes of TNF1 (2308G).
Lane 3 is a homozygote of TNF2 (308A), and lanes 2 and 4 are heterozy-
gotes of TNF1 and TNF2.
were accompanied with hypertension and significant de-
grees of proteinuria (.1.5 g/day). There was no statisti-
cally significant difference between progressors and non-
of 87 bp and 20 bp, and TNF2 (308A), which gave a progressors in terms of sex distribution, disease duration,
single 107 bp fragment (Fig. 2). and duration of follow-up. The allele frequency and car-
riage rate are shown in Table 2. The observed distribu-
Statistics tion of homozygotes and heterozygotes conformed to
Allele frequency was calculated as the number of oc- Hardy–Weinberg expectations. Most patients carried
currences of the test allele in the population divided IL1RN*1 and TNF1 (carriage rate, 100 and 99.1%, re-
by the total number of alleles. The carriage rate was spectively). An excessive carriage of IL1RN*2 was found
calculated as the number of individuals carrying at least in the patient group as compared with the normal con-
one copy of the test allele divided by the total number trols (allele frequency, 9.9 vs. 2.5%, P , 0.0001; carriage
of individuals. The correlation between polymorphism rate, 19.8 vs. 4.0%, P , 0.0001). When the patients were
and clinical parameters was analyzed using Fisher’s exact stratified into subgroups, there was a trend toward an
test. A Bonferoni correction was made for multiple com- increased allele frequency and carriage rate of IL1RN*2
parisons. Renal survival analysis in patients carrying the among those with gross hematuria and with progressive
specific allele was performed by Kaplan–Meier’s method disease, although this phenomenon did not reach statisti-
and was compared with a log rank test. cal significance. However, patients with gross hematuria
were associated with a higher rate of TNF2 carriage as
compared with those did not have gross hematuria (alleleRESULTS
frequency, 15.4 vs. 4.6%, P 5 0.0552; carriage rate, 30.8
Table 1 gives the patients’ characteristics. A total of vs. 8.2%, P 5 0.0272; Table 3 and Fig. 3). When the
111 cases, including 57 male and 54 female patients, was renal survival rate was analyzed, the carriage of TNF2
enrolled. The mean duration of disease was 66.8 6 47.2 had no impact on the survival (Fig. 4). However, patients
months (range, 0 to 288 months), and the duration of who carried IL1RN*2 had a significantly shorter period
follow-up was 47.3 6 32.6 months (range, 0 to 132 of long-term survival as compared with those without
months). During the follow-up period, 45 out of 111 IL1RN*2 (Fig. 5). The median survival time was 134
cases (40.5%) were classified as progressors. Of these, months for the IL1RN*2 (1) group and 72 months for
34 patients reached end-stage renal failure and were the IL2RN*2 (2) group (P , 0.01).
on maintenance dialysis, and 3 patients had predialysis
advanced renal failure (serum creatinine . 5 mg/dL); 3
DISCUSSIONwere in modest renal failure (serum creatinine 2 to 5
mg/dL), and 5 had mild renal insufficiency (serum creati- Interleukin-1 receptor antagonist is an 18 kD glyco-
protein produced by macrophages/monocytes and poly-nine between 1.3 and 2.0 mg/dL). All of the progressors
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Table 3. Association of allele frequency with clinical parameters
Allele frequency % Carriage rate %
IL1RN*2 TNF2 IL1RN*2 TNF2
N 1ve 2ve 1ve 2ve 1ve 2ve 1ve 2ve
Mild 87 9.8 90.2 6.3 93.7 19.5 80.5 11.5 88.5
Severe 24 10.4 89.6 4.2 95.8 20.8 79.2 8.3 91.7
With gross hematuria 13 15.4 84.6 15.4a 84.6 30.8 69.2 30.8b 69.2
Without gross hematuria 98 9.2 90.8 4.6 95.4 18.4 81.6 8.2 91.8
Progressor 45 12.2 87.8 4.4 95.6 24.4 75.6 8.9 91.1
Nonprogressor 66 8.7 91.5 8.9 90.1 16.9 83.1 12.3 87.7
aP 5 0.0276, bP 5 0.0136 as compared to those without gross hematuria
Fig. 3. Carriage rate of TNF2 (2308A) in dif-
ferent subgroups of IgA nephropathy (IgAN)
patients. A significantly higher rate was ob-
served in patients with a history of gross hema-
turia (GH). Abbreviations are: prog, prog-
ressors; nonprog, nonprogressors.
Fig. 4. Renal survival analysis in IgAN pa-
tients with or without TNF2. There was no
significant difference between TNF2 (1)
(dashed line) and TNF2 (2) (solid line) pa-
tients. The numbers on the graph represent
numbers of patients remaining at each time
point.
morphonuclear cells [8, 9], and it is structurally related psoriasis [14], alopecia areata [15], and ulcerative colitis
[16]. In patients with systemic lupus erythematosus, theto IL-1a and IL-1b with a homology in amino acid se-
quence of 19 and 26%, respectively. It specifically inhib- IL1RN*2 carrier showed a picture of more intensive
disease, in particular with photosensitivity and discoidits IL-1 activity by competing for receptor binding and is
one of the most powerful endogenous anti-inflammatory skin lesions [17]. In diabetes mellitus patients, the car-
riage of IL1RN*2 was associated with an increased riskagents. Recombinant IL-1ra has been found to suppress
experimental crescentic GN [10, 11] and IgAN in mice of diabetic complications, especially diabetic nephropa-
thy [19]. The mechanism underlying this association is[12]. Studies of the IL-1ra gene have documented a poly-
morphism within intron 2. Five different alleles have still speculative. It was thought that individuals carrying
IL1RN*2 might produce less IL-1ra [19], thereby beingbeen characterized according to the number of tandem
repeats of an 86 bp sequence [13]. Individuals carrying predisposed to inflammation. However, the levels of in-
tracellular IL-1ra mRNA from keratinocytes with differ-the IL1RN*2 allele were found to be associated with
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Fig. 5. Renal survival analysis in IgAN pa-
tients with (solid line) or without (dashed line)
IL1RN*2. Patients carrying IL1RN*2 were as-
sociated with a significantly shorter length of
long-term survival; the median survival time
for IL1RN*2(2) was 134 months and for
IL1RN*2(1) was 72 months.
ent intron two alleles were not significantly different IL-6, TNF-a, interferon-g, and platelet-derived growth
factor [6]. The number of glomerular infiltrating macro-[27]. In contrast, increased IL-1ra synthesis had been
demonstrated in diabetic patients [28] and normal indi- phages/monocytes positive for IL-1a correlated with
mesangial cell proliferation, whereas interstitial cellsviduals carrying IL1RN*2 [29, 30]. However, the enhanc-
ing effect of IL1RN*2 on plasma IL-1ra level requires positive for IL-1a correlated with the grade of tubuloin-
terstitial changes and proteinuria in IgAN patients [4].the presence of the IL-1b-511 allele 2 or the absence of
the IL-1b 13953 allele 2, suggesting that the IL-1b gene Increased excretion of TNF-a and IL-1b in urine from
patients with IgAN and Henoch-Scho¨nlein purpura wasparticipates in the regulation of IL-1ra production [30].
It is speculated that individuals carrying IL-1b-511 allele 2 also characterized [34]. Because IL-1 activity depends on
the IL-1 to IL-1ra ratio [35], and as discussed previously,or with the absence of the IL-1b 13953 allele 2 produce
an abundance of IL-1, which, in turn, triggers a strong patients carrying IL1RN*2 may have increased produc-
tion of IL-1ra and IL-1b, it is reasonable to speculateIL-1ra production in the IL1RN*2 carriers because IL-1
is a strong inducer of IL-1ra [31]. Therefore, IL1RN*2 that the administration of IL-1 blockade or IL-1ra en-
hancer may have a beneficial effect in the treatmentis probably a marker for a linked disease-associated locus
rather than a direct disease-associated allele. Studies of IgAN. In this regard, treatment with IL-1ra in an
experimental model of crescentic glomerulonephritiswith normal control subjects showed that IL1RN*2 was
associated mainly with disease severity rather than sus- showed a significant reduction of proteinuria and a recov-
ery of normal renal function [11, 36]. In a spontaneouslyceptibility. Recently, an increased rate of IL1RN*2 car-
riage was found in IgAN patients with gross hematuria occurring model of IgAN in mice, treatment with IL-1ra
was associated with a significant reduction of proteinuriaand Henoch-Scho¨nlein purpura, leading to the postula-
tion of a genetic link between these two groups of patients and improvement of renal 51Cr-EDTA clearance [12].
Tumor necrosis factor-a is also a potent cytokine in-[20]. The current study also showed a higher allele fre-
quency of IL1RN*2 (15.4%) among those with gross he- volved in many glomerular diseases, including IgAN
[4, 21, 37, 38]. TNF-a may be produced locally in kidneymaturia as compared with those without gross hematuria
(9.2%), although this did not reach statistical significance cells [6, 32] or derived from circulating macrophages/
monocytes [6, 39] in IgAN. A study of cytokine expres-and was probably caused by a relatively small population
of those with gross hematuria (N 5 13). Interestingly, for sion in IgAN patients showed that over 90% were posi-
tive for TNF-a, from both peripheral blood mononuclearthe first time, we demonstrated a significantly increased
allele frequency and a carriage rate of IL1RN*2 in pa- cells and kidney tissue [6]. More recently, Inaba et al
documented a significantly higher serum TNF-a level intients with IgAN and a lower long-term renal survival
rate among IgAN patients carrying IL1RN*2. IgAN patients with gross hematuria than in those with
only microscopic hematuria [40]. TNF-a tended to de-The role of IL-1 in the pathogenesis of IgAN has
been thoroughly studied. IL-1 promotes mesangial cell crease after the macroscopic hematuria disappeared. It
is interesting to find that in our study, patients carryingproliferation [2] and extracellular matrix production [7].
IL-1 can be produced either locally in the glomeruli [32] TNF2 who were supposed to have increased TNF-a tran-
scription [23] were also associated with gross hematuria,or by peripheral blood mononuclear cells [33] in patients
with IgAN. A phenotypic study of cytokine expression thus providing a genetic basis for the previous clinical
observation [40].in the kidneys of IgAN patients found that IL-1 was one
of the most commonly identified cytokines other than To our knowledge, the significance of carriage of TNF2
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2. Wardle EN: Cytokines as growth factors and glomerulonephritis.in IgAN patients has not been previously addressed. The
Nephron 57:257–261, 1991
carriage of TNF2 has been found to be associated with 3. Montinaro V, Hevey K, Aventaggiato L, Fadden K, Esparza
A, Chen A, Finbloom DS, Rifai A: Extrarenal cytokines modulateseveral inflammatory diseases, including alopecia areata
the glomerular response to IgA immune complexes. Kidney Int[24], rheumatoid arthritis [25], and systemic lupus erythe-
42:341–353, 1992
matosus [26], implicating a pathogenetic role of TNF-a 4. Yoshioka K, Takemura T, Murakami K, Okada M, Yagi K, Miya-
zato H, Matsushima K, Maki S: In situ expression of cytokinesin these diseases. It seemed that the carriage of the TNF2
in IgA nephritis. Kidney Int 44:825–833, 1993allele was associated with an increase in disease suscepti-
5. Chen A, Chen WP, Sheu LF, Lin CY: Pathogenesis of IgA ne-
bility rather than disease activity [24–26]. A study of phropathy: In vitro activation of human mesangial cells by IgA
immune complex leads to cytokine secretion. J Pathol 173:119–126,TNF-a released by cultured monocytes, either spontane-
1994ously or induced by lipopolysaccharide in IgAN patients,
6. Yano N, Endoh M, Nomoto Y, Sakai H, Fadden K, Rifai A:
showed that the level did not appear to correlate with Phenotypic characterization of cytokine expression in patients with
IgA nephropathy. J Clin Immunol 17:396–403, 1997clinical disease activity as indicated by the degree of
7. Border WA, Noble NA: From serum sickness to cytokines. Labproteinuria, degree of hematuria, erythrocyte sedimenta-
Invest 68:125–128, 1993
tion rate, and creatinine clearance [39]. Although serum 8. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ,
Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC:TNF-a was associated with increased mesangial cell pro-
Interleukin-1 receptor antagonist activity of a human interleukin-1liferation, it was unrelated to the grade of mesangial
inhibitor. Nature 343:336–341, 1990
matrix expansion and the degree of proteinuria [40]. 9. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT,
Hannum CH, Thompson RC: Primary structure and functionalIn experimental models of glomerulonephritis, however,
expression from complementary DNA of a human interleukin-1the infusion of TNF-a and interferon-g was shown to
receptor antagonist. Nature 343:341–346, 1990
cause glomerular endothelial damage and to exacerbate 10. Tang WW, Feng L, Vannice JL, Wilson CB: IL-1 receptor antago-
nist ameliorates experimental anti-GBM antibody associated glo-proteinuria [41]. In our study, the carriage of TNF2 was
merulonephritis. J Clin Invest 93:273–279, 1994not correlated with disease progression and long-term
11. Lan HY, Nikolic-Paterson DJ, Wu W, Vannice JL, Atkins RC:
outcome and did not even correlate with initial disease Interleukin-1 receptor antagonist halts the progression of estab-
lished crescentic glomerulonephritis in the rat. Kidney Int 47:1303–activity except for gross hematuria, suggesting that
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12. Chen A, Sheu LF, Chou WY, Tsai SC, Chang DM, Liang SC,
progression in human IgAN. It is likely that an increased Lin FG, Lee WH: Interleukin-1 receptor antagonist modulates the
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